1. Home
  2. NRXS vs TENX Comparison

NRXS vs TENX Comparison

Compare NRXS & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuraxis Inc.

NRXS

Neuraxis Inc.

HOLD

Current Price

$4.44

Market Cap

76.9M

Sector

N/A

ML Signal

HOLD

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

SELL

Current Price

$1.35

Market Cap

73.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
NRXS
TENX
Founded
2011
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.9M
73.8M
IPO Year
2023
2001

Fundamental Metrics

Financial Performance
Metric
NRXS
TENX
Price
$4.44
$1.35
Analyst Decision
Strong Buy
Buy
Analyst Count
2
10
Target Price
★ $11.00
$10.29
AVG Volume (30 Days)
146.5K
★ 1.3M
Earning Date
11-09-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 22.13
N/A
EPS
★ N/A
N/A
Revenue
★ $3,569,282.00
N/A
Revenue This Year
$118.53
N/A
Revenue Next Year
$101.28
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 32.89
N/A
52 Week Low
$2.50
$1.31
52 Week High
$9.33
$19.40

Technical Indicators

Market Signals
Indicator
NRXS
TENX
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
NRXS
TENX

About NRXS Neuraxis Inc.

Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: